{
  "as_of": "2026-02-07",
  "clinical_trials": [
    {
      "item_id": "milvexian",
      "trial_name": "LIBREXIA AF",
      "nct_id": "NCT05757869",
      "note": "Milvexian vs apixaban in AF"
    },
    {
      "item_id": "milvexian",
      "trial_name": "LIBREXIA STROKE",
      "nct_id": "NCT05702034",
      "note": "Milvexian after ischemic stroke or high-risk TIA"
    },
    {
      "item_id": "asundexian",
      "trial_name": "OCEANIC-STROKE",
      "nct_id": "NCT05686070",
      "note": "Asundexian after non-cardioembolic stroke or high-risk TIA"
    },
    {
      "item_id": "ap31969",
      "trial_name": "AP31969 Phase 2",
      "nct_id": "NCT07267949",
      "note": "SK ion channel inhibitor in AF"
    },
    {
      "item_id": "sphere-360",
      "trial_name": "Sphere-360 European study",
      "nct_id": "NCT05115214",
      "note": "Affera PFA system European study"
    },
    {
      "item_id": "cellfx-nspfa-360",
      "trial_name": "CellFX nsPFA 360 feasibility",
      "nct_id": "NCT06696170",
      "note": "Pulse Biosciences nsPFA cardiac catheter system"
    },
    {
      "item_id": "cellfx-nspfa-surgery",
      "trial_name": "NANOCLAMP AF",
      "nct_id": "NCT06959121",
      "note": "Pulse Biosciences nsPFA surgical clamp system"
    },
    {
      "item_id": "iclas",
      "trial_name": "iCLAS U.S. IDE",
      "nct_id": "NCT04061603",
      "note": "Adagio iCLAS ULTC cryoablation system in persistent AF"
    },
    {
      "item_id": "episense",
      "trial_name": "CONVERGE",
      "nct_id": "NCT01984346",
      "note": "Hybrid convergent AF ablation"
    },
    {
      "item_id": "insightpfa-lotospfa",
      "trial_name": "InsightPFA",
      "nct_id": "NCT06014996",
      "note": "Nanosecond PFA vs RFA randomized trial"
    },
    {
      "item_id": "spherepvi",
      "trial_name": "SpherePVI",
      "nct_id": "NCT05144503",
      "note": "SpherePVI safety and performance study"
    },
    {
      "item_id": "thrv-1268",
      "trial_name": "THRV-1268 Phase 1",
      "nct_id": "NCT06507839",
      "note": "Thryv Therapeutics SGK1 inhibitor Phase 1"
    },
    {
      "item_id": "ap30663",
      "trial_name": "AP30663 Phase 2",
      "nct_id": "NCT04571385",
      "note": "Acesion SK channel inhibitor cardioversion in AF"
    },
    {
      "item_id": "hbi-3000",
      "trial_name": "HBI-3000-402",
      "nct_id": "NCT04680026",
      "note": "Sulcardine derivative IV cardioversion study"
    },
    {
      "item_id": "regn7508",
      "trial_name": "ROXI-ATLAS",
      "nct_id": "NCT07175428",
      "note": "Regeneron FXI antibodies AF safety trial"
    },
    {
      "item_id": "regn9933",
      "trial_name": "ROXI-ATLAS",
      "nct_id": "NCT07175428",
      "note": "Regeneron FXI antibodies AF safety trial"
    },
    {
      "item_id": "ciraparantag",
      "trial_name": "Ciraparantag edoxaban reversal",
      "nct_id": "NCT01826266",
      "note": "Phase 2 healthy volunteer reversal study"
    },
    {
      "item_id": "conformal-claas",
      "trial_name": "CONFORM Pivotal",
      "nct_id": "NCT05147792",
      "note": "Conformal CLAAS pivotal IDE trial"
    },
    {
      "item_id": "seala-laac",
      "trial_name": "SeaLA study",
      "nct_id": "NCT05911685",
      "note": "SeaLA LAAC prospective multicenter study"
    },
    {
      "item_id": "pkn605",
      "trial_name": "CPKN605A12201",
      "nct_id": "NCT07217067",
      "note": "Novartis Phase 2 AF burden study"
    },
    {
      "item_id": "shr-2004",
      "trial_name": "SHR-2004-102",
      "nct_id": "NCT06280768",
      "note": "Hengrui FXI antibody Phase 1b in AF"
    },
    {
      "item_id": "lambre-ii",
      "trial_name": "LAMBRE II clinical study",
      "nct_id": "NCT07385599",
      "note": "Lifetech LAMBRE II next-generation LAAC study"
    },
    {
      "item_id": "sepiola-laac",
      "trial_name": "Sepiola safety and performance study",
      "nct_id": "NCT06099106",
      "note": "Endomatic Sepiola LAA closure device study"
    },
    {
      "item_id": "cala-neuromod",
      "trial_name": "AFIB-01",
      "nct_id": "NCT05653583",
      "note": "Cala wearable neuromodulation feasibility study"
    },
    {
      "item_id": "botox-poaf",
      "trial_name": "NOVA",
      "nct_id": "NCT03779841",
      "note": "Botulinum toxin type A for POAF prevention"
    },
    {
      "item_id": "maxwell-srt",
      "trial_name": "SR-TheAF / SRT first-in-human",
      "nct_id": "NCT05461612",
      "note": "MaxWell SRT first-in-human study"
    }
  ],
  "press_releases": [
    {
      "item_id": "milvexian",
      "label": "BMS Librexia ACS update",
      "url": "https://investors.bms.com/iframes/press-releases/press-release-details/2025/Update-on-Phase-3-Librexia-ACS-Trial/default.aspx"
    },
    {
      "item_id": "asundexian",
      "label": "Bayer OCEANIC-AF stop",
      "url": "https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/"
    },
    {
      "item_id": "asundexian",
      "label": "Bayer OCEANIC-STROKE ISC 2026",
      "url": "https://www.bayer.com/media/en-us/bayers-asundexian-demonstrated-a-substantial-26-percent-reduction-in-stroke-after-a-non-cardioembolic-ischemic-stroke-or-high-risk-transient-ischemic-attack-with-no-increase-in-isth-major-bleeding-versus-placebo/"
    }
  ]
}
